The rise of the rivastigmine market is mostly driven by the expanding senior population.

Rivastigmine is an inhibitor of the cholinesterase enzymes butylcholinesterase and acetylcholinesterase. It's a cholinergic agent that helps with Alzheimer's and Parkinson's disease treatment. Because of its tiny molecular size, the medicine can be taken orally or applied as transdermal patches.

During the forecast period, between 2021 and 2026, the global Rivastigmine market is expected to grow at a significant rate. The market is likely to develop at a steady rate through 2020, thanks to key players' increasing adoption of tactics.


Rivastigmine market revenue was million dollars in 2016, increased to million dollars in 2020, and is expected to reach million dollars in 2026, with a CAGR of during 2020-2026.

Rivastigmine Market – Dynamics

The growing senior population is a primary driver of the rivastigmine market's expansion. According to the Alzheimer's Association, the chance of developing dementia doubles every five years beyond the age of 65. Furthermore, as the global incidence of cardiovascular disorders rises, so does the occurrence of Alzheimer's disease, driving up demand for rivastigmine. According to the National Center for Biotechnology Information, the global incidence of cardiovascular illnesses was roughly 22.5 per 1,000 people in 2013, implying a dementia risk. Dementia can be exacerbated by diseases including diabetes and high blood pressure, which drive up demand for rivastigmine and propels the market forward.

Rivastigmine Market – Regional Insights

Geographically, the rivastigmine market is divided into North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa. In 2017, North America held the greatest proportion of the global rivastigmine market. This is due to the region's rising prevalence of chronic renal illness, which can lead to dementia. Chronic kidney disease affected roughly 31 million people in 2015, according to the American Kidney Fund. In 2017, Europe accounted for the second-biggest revenue share in the worldwide rivastigmine market, owing to the region's growing elderly population. Dementia is more common among the elderly population. According to World Population Prospects (WPP), roughly 25% of Europe's population was 60 years old or older in 2017. According to the Alzheimer's Association, Latin America and Africa had a high prevalence of vascular illnesses in 2017. As a result, tremendous expansion in Latin America and Africa is predicted in the global rivastigmine market during the forecast period.


Rivastigmine Market – Competitive Landscape

Major players operating in the global rivastigmine market include, Novartis Europharm Limited, Actavis Pharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market are focused on product development and approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease.


Comments

Post a Comment

Popular posts from this blog

Continuous Glucose Monitoring (CGM) Devices Market -Dynamics and Forecast

Image
CGM (Continuous Glucose Monitoring) technology allows you to monitor your glucose levels 24 hours a day using a sensor that delivers the data to a MiniMed insulin pump. However, these devices also aid in diabetes management by lowering individual insulin dosages. These gadgets' integrated software provides users with information about food consumption, medication, physical activity, and ailments.  As a result, an increasing number of diabetic patients are relying on these devices to control and treat their condition, propelling market growth. A growing number of continuous glucose monitoring devices are being integrated with apps and software to treat people with diabetes mellitus, thanks to the development of digital medicines.The rising prevalence of diabetes mellitus has boosted the market for continuous glucose monitoring (CGM) devices. The Continuous Glucose Monitoring (CGM) Market is estimated to develop at a CAGR of 14% over the forecast period. High blood glucose levels oc...
Read more

YOU YES YOU!

Image
Welcome to Riya's  blog! HEY Everyone! So this is my my very first blog and  i am quite excited about it. WELL  I am  a 21 years old girl who sees the world through her eyes just like everyone else. I believe each of us have their own views and opinions about every little thing that we see through our eyes wide open and that is  what individuality is ! Having our own brains , hobbies,rights,skills , gifts ,flaws and i certainly believe that embracing them is one of the best things a human could do. Okay well so the topic on what  i am going to throw a little  light on here is not self love or self respect or being righteous , strong or anything like that , My topic here is going to be "YOU"   . "YOU" can be anyone here including me 'YOU' = "Individual" Isn't it so weird that in a world having  millions and millions of people  with their own "IDENTITIES " still lack " INDIVIDUALITY ". You know why? because...
Read more

Key Benefits of Breath Analyzer Market

Image
The Breath Analyzer is a gadget that uses a breath sample to determine an individual's Blood Alcohol Content (BAC). The test is based on the link between the amount of alcohol in the blood and the amount of alcohol in the breath going through the lungs. The use of breath analyzer equipment has increased as the trend for severe alcohol intake has increased, resulting in traffic accidents.  Government actions that favor the market are also propelling it forward. Breathalyzer devices are also gaining popularity as a result of the growing demand for accurate BAC (blood alcohol content) levels at work, as well as their non-invasive nature, which is driving up demand for breath analyzer equipment. It's a must-have tool for keeping track of drugs, alcohol, TB, and asthma. and other diseases hence; it is projected that the demand for this system should constantly rise.  Inaccurate analysis, on the other hand, might lead to wrong diagnosis, which is the market's main constrai...
Read more